PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
18.48%
Positive revenue growth while CVE is negative. John Neff might see a notable competitive edge here.
32.96%
Positive gross profit growth while CVE is negative. John Neff would see a clear operational edge over the competitor.
-5.94%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-5.94%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-31.82%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-32.50%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-31.93%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
38.84%
OCF growth above 1.5x CVE's 19.77%. David Dodd would confirm a clear edge in underlying cash generation.
198.09%
Positive FCF growth while CVE is negative. John Neff would see a strong competitive edge in net cash generation.
2.64%
10Y revenue/share CAGR under 50% of CVE's 28.98%. Michael Burry would suspect a lasting competitive disadvantage.
-34.07%
Negative 5Y CAGR while CVE stands at 28.98%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-77.73%
Negative 3Y CAGR while CVE stands at 28.98%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
-11.21%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-55.45%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-52.11%
Negative 10Y net income/share CAGR while CVE is at 402.88%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-90.29%
Negative 5Y net income/share CAGR while CVE is 402.88%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-96.56%
Negative 3Y CAGR while CVE is 402.88%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
357.84%
Equity/share CAGR of 357.84% while CVE is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-1.47%
Negative 5Y equity/share growth while CVE is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-28.54%
Negative 3Y equity/share growth while CVE is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
101.92%
Dividend/share CAGR of 101.92% while CVE is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
-49.90%
Negative near-term dividend growth while CVE invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-5.19%
Firm’s AR is declining while CVE shows 8.91%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-50.00%
Inventory is declining while CVE stands at 13.68%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-0.60%
Negative asset growth while CVE invests at 6.39%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-2.42%
We have a declining book value while CVE shows 5.33%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
1.88%
We have some new debt while CVE reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-35.82%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.